. The pathogenesis of the hypercalcemia associated with multiple myeloma has been attributed to excessive bone resorption (3) . Carbohydrate-active steroids have been successfully used to correct hypercalcemia associated with sarcoidosis (4), idiopathic hypercalcemia of infancy (5) , and neoplastic diseases including multiple myeloma (6) . In idiopathic hypercalcemia of infancy and sarcoidosis, diseases in which calcium absorption is increased, cortisone has been shown to increase total fecal calcium (4, 5) . Steroids may also alter calcium metabolism of bone (7) and modify calcium transport in the renal tubule (8) . In a single patient with multiple myeloma and hypercalcemia, corticosteroid administration was associated with net calcium retention and decreased bone resorption (3) . The present study was designed to further study the effects of prednisone 1 on calcium metabolism in patients with multiple myeloma and hypercalcemia. Steroid-induced reversal of hypercalcemia is associated with a decrease in the miscible pool size and a distinct reduction in bone resorption.
Methods
Patients. Of the seven patients studied, five had multiple myeloma (Table I) . Two control patients ("normals") without multiple myeloma or bone disease were studied (Table I ). All patients were hospitalized in an * Submitted for publication February 11, 1964 ; accepted July 9, 1964. Part of this work has appeared in abstract form (1) . t Present address: Biophysical Laboratory, Harvard
Medical School, Boston, Mass. 02115.
1 17a,2lDihydroxy-1,4-pregnadiene-3,1 1,20-trione.
air-conditioned metabolic ward and were ambulatory throughout the study. Experimental design. All patients except G.J. were studied in a control phase of 15 to 24 days followed immediately by a treatment phase of 15 to 18 days. In addition, two patients (D.F. and W.G.) with multiple myeloma were restudied after cessation of prednisone therapy. These recovery phases of 6 and 10 days respectively were begun 5 and 10 days after the last dose of prednisone. One patient, E.B., was studied in reverse order, the treatment phase preceding the control phase. Because of adrenal insufficiency that developed on attempted prednisone withdrawal, E.B. was treated with physiological doses of prednisone (7.5 mg per day) during the control phase. Patient G.J. was studied for only 3 days before therapy. Treatment consisted of prednisone, 10 to 20 mg, administered orally every 6 or 8 hours. Except for G.J., Ca"7 kinetic studies were performed at least twice on each patient, once during the control phase and again 5 to made on pooled 5-or 6-day specimens. Ca, Na, and P were usually analyzed from daily urine samples. Urinary nitrogen (N) was analyzed from 5-or 6-day pooled specimens. The following analytical methods were used: nitrogen, macro-Kjeldahl (9); urinary, dietary, and fecal phosphorus, Taussky and Shorr (10); serum phosphorus, Reiner (11); stool, dietary, and urinary calcium, Kochakian and Fox (12) ; serum calcium, MacIntyre (13); serum alkaline phosphatase, King and Armstrong (14) ; and serum and urinary creatinines, Chassen, Grady, and Stanley (15) . Diffusible serum calcium was measured under 5% C02 at 23°C on previously frozen, stored serum by the method of Toribara, Terepka, and Dewey (16) . Sodium and potassium were analyzed on the Patwin flame photometer. Hydroxyproline, determined by the method of Prockop and Udenfriend (17) , was measured from daily samples of urine. A minimum of four determinations was made at 2-to 4-day intervals when patients were receiving no therapy and again during prednisone treatment. The patients were not on low hydroxyproline diets. Renal function was evaluated two to four times a week by determining 24-hour endogenous creatinine clearances. All clearance results are presented uncorrected for body surface area.
Intravenous Ca"7 studies. Ca'7 (physical half life, 4.7 days) had a specific activity of 20 mc per g. Before administration to patients, a sample of the original Ca"7 solution was sterilized and then assayed for radioactivity, along with standards prepared at the same time. The error in the radioassay was calculated to be less than 8%. The isotope was administered intravenously in water. Fifteen or 20 /Ac of Ca'7C12 in 5 ml of isotonic saline was administered intravenously to each patient (except C.R. and W.G.) during the control phase of study and the same dosage repeated 5 to 8 days after prednisone treatment had been instituted. Patient C.R. received two injections of 6.5 uc each, and W.G. received an additional 14 ,uc during the recovery period. Fifteen days after the intravenous administration of 15 to 20 uc Ca"7, urine, stool, and serum radioactivity had returned to a count rate that was not statistically different from background. All counting was done in a single channel gamma ray spectrometer, with the lower gate set at 400 kev to exclude daughter decay product, Sc'7. Serum samples were obtained at 12-to 24-hour intervals, and 2-or 4-ml samples were counted in an automatic well-type scintillation counter.3 Five-hundred-ml samples of 24-hour urine collections and 500-ml samples of 1-or 2-day homogenized stool collections were counted in quart paint cans in a well-type scintillation counter.4 Assayed standards were prepared to conform to the geometry of the serum or stool and urine samples and were counted in the same manner. Appropriate correction was made for fecal lag in Ca'7 excretion. All samples obtained within the first week after the Ca"7 injection were counted sufficiently long to insure a counting error of less than 2%. Results were expressed as percentages or fractions of administered dose.
Oral Ca"7 studies and calcium absorption. In three patients with multiple myeloma, studies of calcium absorption were performed during the first week of the balance study or during trial balance and were repeated 15 to 20 days after the institution of prednisone therapy.
The isotope (0.4 to 0.5 /Ac) was administered orally during breakfast. Stools were counted until radioactivity returned to background. Absorption was calculated from the equation, net Ca absorption (milligrams per day) = (1 -Fe) X dietary Ca (milligrams per day), where Fe = fraction of orally administered dose recovered in the stool.
Calcium kinetics. The conceptual model employed to determine the miscible calcium pool (E) and the bone formation rate (BFR) was taken from Heaney and Whedon (18) . Serum specific activity was measured from 48 hours until 0 and plotted semilogarithmically. O is defined as the temporal point at which the slope of the Ca'7 disappearance curve becomes less negative (120 to 216 hours) (18) . The ordinate intercept (extrapolation of the linear portion of the specific activity curve to zero time) and the slope (k) of the serum specific activity curve were determined by the method of least squares (19) using five to nine specific activity values from 48 hours to 0. E was determined by dividing the ordinate intercept into the total administered dose. BFR was then calculated by the formula proposed by Heaney and Whedon (18): BFR=Ek (1-fu-fs), where E =miscible calcium pool, k= fractional rate of loss of Ca'7 by all routes from E (k = Results The effect of prednisone on serum calcium concentfration. In the four patients with hypercalcemia and myeloma, steroid administration was associated with a reduction in serum calcium (Table II) . A comparison of the average serum calcium concentration measured 4 days before institution of therapy to average measurements obtained during the first 7 days after therapy revealed a mean decrease of 2.2 mg per 100 ml (range, 3.3 to 0.8 mg per 100 ml). In patient E.B., studied initially on higher prednisone dosage, an increase in serum calcium concentration occurred when the prednisone dose was reduced (Table II ). In the three normocalcemic patients, prednisone therapy resulted in a decrease in the mean serum calcium concentration of 0.2 mg per 100 ml (range, 0.4 to 0.1 mg per 100 ml).
Effect of prednisone on calcium balance. During the control phase of study, all seven patients were in negative calcium balance (Table II) . The hypercalcemic patients with multiple myeloma were in a greater degree of negative balance than D.F. and the two normal patients. The patients with multiple myeloma and hypercalcemia had higher urinary and fecal calcium values than did normal subjects on comparable intakes (21) . In four of the five patients with multiple myeloma, the urinary calcium excretion was related to the degree of hypercalcemia, with G.J. showing the (Table II) .
In the patients with multiple myeloma (excluding patient G.J., who had only a 3-day control study) prednisone therapy was associated with a decrease in the mean, net calcium loss (A.M., ELB., and D.F.) or no change in mean calcium balance (W.G.). Thus, at a time when serum calcium concentration was decreasing, the changes in balance were in the direction of relative net calcium retention (Table II) . In contrast, during prednisone treatment, the two normal patients, C.R. and E.R., demonstrated an increased rate of urinary calcium excretion, with a decrease in stool calcium resulting in a slightly more negative balance (Table II) . In these two patients, the enhanced urinary calcium excretion occurred gradually and continued to increase as long as the patients were maintained on prednisone.
Nitrogen and phosphorus balance. In the control phase, all patients were in positive nitrogen balance. with the exception of A.M. and W.G.
All patients with myeloma, with the exception of D.FV., were in negative phosphorus balance during the control phase of study. Prednisone therapy was associated with a net P and N loss. The two patients without bone disease showed similar increased losses of P and N during the treatment phase. Serum Na, K, P, and alkaline phosphatase concentrations did not change during prednisone treatment.
The effect of prednisone on intestinal absorption of calcium. The absorption of Ca47 in patients with myeloma averaged 22% during control periods and 18% during prednisone therapy (Table III). The normal patients, E.R. and C.R., absorbed 55 and 45%, respectively, while on no treatment. In D.F., studied after cessation of prednisone therapy (recovery phase), oral Ca47 absorption increased from 12 and on the renal excretion of calcium and sodium. associated with an increase in calcium excretion The reduction in serum calcium concentration in the urine (Figures 1 and 2) . In three of the after institution of prednisone therapy was not five patients, sodium excretion rose significantly during the first week of prednisone therapy. In two patients, A.M. and W.G., an increase in creatinine clearance was observed after the institution of prednisone therapy (Figures 1 and 2) . In patient D.F., sodium excretion increased from 61 to 89 mEq per day within 3 days after prednisone therapy. However, no change in serum calcium concentration (10.4 to 10.0 mg per 100 ml), calcium excretion (115 to 117 mg per day), or creatinine clearance (55 to 50 ml per minute) occurred.
The effect of prednisone on serum protein1-bomiid calcium. Of the five patients with multiple myeloma, three (A.M., D.F., and W.G.) had an increased total serum protein concentration > 9.0 g per 100 ml (Figure 3 ). Prednisone therapy was associated with reductions in both dialyzable and total serum calcium. Therefore, the percentage of bound calcium remained essentially unchanged (Figure 3) . In three patients, W.G., A.M., and D.F., reduction in the total serum protein concentration, 1 to 1.5 g per 100 ml during prednisone therapy, was due to a decrease in the myeloma protein fraction (Figure 3 ).
Effect of prednisone on Ca47 kinetics. A) Miscible calcium pool (E). In four patients with hypercalcemia, the miscible Ca pool size (E) measured during the control phase was either elevated or at the upper limits of normal (22) (Table III) . During prednisone therapy, the four patients with multiple myeloma (G.J. not included) had a mean reduction in pool size of 25% (range, 17 to 35%, p < 0.05) (19) . Ex- pressed in grams, patient A.M. demonstrated the largest reduction (2.70 g) and D.F., the least change (0.68 g). In the two normal patients the decrease in E was 11 and 22% (p < 0.2).
The 95% confidence limits for the determination of the ordinate intercept and the slope for each of the serum specific activity curves are given in the Appendix. Although all patients showed a similar directional change, there was overlap in the 95% confidence limits in most patients, especially in determination of the ordinate intercept. B) Bone formation rate (BFR). Two of the four hypercalcemia patients had an elevated BFR during their initial study. All four patients with multiple myeloma had a reduction in BFR as a result of prednisone therapy (Table III) . C) Bone resorption rate (BRR). During the control period, BRR was greater than BFR in all patients (Table III) . Hypercalcemic patients with multiple myeloma had the highest BRR and also the greatest differences between BRR and BFR. During prednisone therapy, BRR was reduced in all patients with multiple myeloma (p < 0.05). The normal patients showed no significant change in BRR (Table III) .
In Figure 4 the changes in E, BFR, and BRR during prednisone treatment are expressed as percentage of control. In the patients with multiple myeloma, the mean decrease in BFR was 20%. The change in BRR was relatively greater (mean decrease, 24%). The normal patients had very little change in either BFR or BRR.
In Figure 5 calcium balance data are shown for W.G. in relation to the Ca47 kinetic studies. During control, hypercalcemia was associated with an elevated urinary calcium excretion, and E was 112 mg per kg (5.37 g). After prednisone therapy, the serum calcium returned to normal withinHydroxyproline excretion. In all patients with multiple myeloma, the mean hydroxyproline excretion measured during the control phase was higher than that measured during the treatment phase (Table IV) (Table IV ). 
Discussion
Evaluation of the method. The model system for calcium metabolism employed in these studies was suggested by Heaney and Whedon and others (18, 20) . Since (20) . In most human studies, including patients with multiple myeloma (24) , the serum specific activity decreases monoexponentially from 36 to 210 hours after a single intravenous injection of a calcium isotope. During this time, the miscible calcium pool, the bone formation rate or accretion rate, and if calcium balance is included, the bone resorption rate can be determined (20) . In repetitive studies on the same patient, determination of E by the simplified method (extrapolation of the linear portion of the specific activity curve to 0) is justified if E is relatively small and if changes in disease activity or calcium metabolism between the two studies are not great (25) . In these studies the patient served as his own control. Similar portions of the specific activity curve were analyzed during each phase of study, and control studies immediately preceded or followed treatment studies. However, in performing Ca47 studies in close time sequence, even though serum radioactivity is within background counting error, it is possible that isotope fixed to bone from a previous injection might recycle due to bone resorption and influence the serum specific activity curve. Total body counting studies demonstrate a continued loss of previously injected Ca47 for periods up to 1 month, but the rate of loss, even in multiple myeloma, is less than 2% per day (26) . Recycling of previously administered isotope would cause a reduc- were calculated by the method of least squares using a minimum of six determinations taken between days 2 and 6. The decrease in negative slope of the specific activity curve at day 5 or 6 formed 0. In the balance graph, intake is plotted downward; fecal excretion (solid area) and urinary excretion (crosshatched area) are plotted upward. tion in the negative slope of the second serum specific activity curve. However, in four of five patients studied, the slope of the serum specific activity curve became more negative rather than less negative in the second study performed during prednisone treatment. In repetitive studies in dogs using Ca47, a 15-day interval between studies was considered sufficient to exclude significant error from previous isotope administration (27) .
Effect of prednisone on calciltut metabolismll. In all hypercalcemic patients \Vith multiple myeloma, a reduction in serum calcium concentration and miscible pool size was observed during prednisone therapy. According to the model of calciumll metabolism used in these studies, calcium may leave the miscible pool by excretion through the gastrointestinal tract or kidney or through accretion into bone (bone formation). Calcium enters the miscible pool through bone resorption or gastrointestinal absorption. If the primary effect of prednisone in these patients were to increase excretion of calcium from the pool through the kidney or gastrointestinal tract, calcium balance should become more negative during predni- . )f sone treatment. An inhibitory effect on calcium absorption by prednisone would also increase total fecal calcium, thereby increasing negative calcium balance, providing endogenous fecal excretion remained unchanged. However, calcium balance either did not change or became less negative during treatment, and in no instance could balance changes account for pool size reduction.
Negative calcium balance in multiple myeloma, even on high dietary intakes, is a common observation (24, 28) , and an amelioration of negative calcium balance in patients with myeloma during therapy with carbohydrate-active steroids has been previously observed (29, 30) . In the present balance studies, it seems unlikely that the improvement in the degree of negative calcium balance was due to adaptation to a low calcium intake, which in normals requires 2 to 3 months (21). Also, it seems unlikely that spontaneous improvement in disease activity could account for observed calcium balance changes, since control studies were performed immediately before treatment.
Balance data indicated that major changes in gastrointestinal calcium absorption did not occur during prednisone therapy. This impression was confirmed in three patients with multiple myeloma studied by oral Ca47 administration. Prednisone produced a small decrease in Ca47 absorption in two of the three patients, but in each case the change could account for only a minute fraction of the change in pool size. In the third patient, no change in Ca47 absorption was noted after institution of prednisone therapy. Since the method used measured total fecal Ca47 activity, it measured both unabsorbed Ca47 and absorbed Ca47 recycled through endogenous secretion. However, the latter component has been shown to account for a small fraction of the recovered isotope (31) . The percentage of absorption measured by oral administration of Ca47 agreed within ±+ 10% with values obtained using a total body counter (32) . Calcium absorption ranged from 12 to 30%o in the patients with myeloma, compared to values of 40 to 70% observed in normal subjects in the present study and previously reported (20, 33) .
In patients with myeloma and hypercalcemia, prednisone resulted in a prompt fall in serum calcium and a gradual, inconstant reduction in urinary calcium excretion, suggesting an increase in calcium clearance. Such an increase could result from decreased tubular reabsorption, increased glomerular filtration, or both. The latter possibility was suggested by increased endogenous creatinine clearances in two patients, but small changes in tubular reabsorption may also have occurred. A transient rise in renal calcium clearance following institution of prednisone therapy could account for the rapid reduction in serum calcium concentration observed in the hypercalcemic patients with multiple myeloma. This explanation would, by necessity, separate the mechanism of the fall in serum calcium from that of the reduction in miscible pool size and would contend that the latter observation resulted from induced alterations in exchange between the miscible pool and skeletal calcium stores. Alternatively, the effects of prednisone observed in these patients can be ascribed to changes in skeletal metabolism alone. Sissons reported that the decreased bone formation observed in patients with Cushing's syndrome was due to impaired osteoblastic activity in the presence of normal osteoclastic function (7). Clark, Geoffroy, and Bowers found that hydrocortisone decreased Ca45 uptake by the rat femur (34) . Other studies have been reported which show that adrenal carbohydrate-active steroids may also alter the rate of bone resorption (35) (36) (37) (38) . Lazor and Rosenberg, reporting data obtained from a single patient with multiple myeloma and hypercalcemia, observed a reduction in bone formation rate and bone resorption rate when hypercalcemia was corrected by prednisone (3) . Similarly, in our four patients with multiple myeloma who had control and treatment Ca47 studies, prednisone therapy was associated with a decrease in both the bone formation rate and bone resorption rate. To explain the reduction in miscible calcium pool size in these patients according to the conceptual model, it is necessary to conclude that the reduction in the bone resorption rate was relatively greater than the reduction in bone formation rate. We propose, therefore, that prednisone modified existing equilibrium conditions in bone, favoring a reduction in miscible pool size, which in turn, was (28, 30) . In our patients, anomalous serum protein concentration decreased in all in which it was initially elevated (Figure 4) . A decrease in percentage of plasma cells was observed in the bone marrow in all three of the patients in which it was examined. Assuming that the high rate of bone resorption is due to myeloma cell activity, an antitumor effect of prednisone would decrease the rate of calcium loss into the miscible pool, accounting for the observed differences between the myeloma and the normal patients.
Summary
Five patients with multiple myeloma, four of whom were hypercalcemic, and two "normocalcemic" patients without bone disease or multiple myeloma were studied by combining metabolic balance and Ca47 kinetic studies to determine the effect of prednisone on calcium metabolism. Prednisone therapy resulted in a reduction in serum calcium concentration in all hypercalcemic patients but was without effect in the patients with normal serum calcium concentrations. In patients with multiple myeloma, prednisone therapy was associated with a decrease in the degree of negative balance or no change in calcium balance. Miscible calcium pool size, bone formation rate, and bone resorption rate as determined by Ca47 kinetic studies were elevated in the hypercalcemic myeloma patients and were reduced by prednisone therapy. Only small changes in calcium absorption and renal calcium transport were observed during prednisone therapy. No 
